Medtronic received information via literature comparing percutaneous pulmonary valve implantation (ppvi) versus surgical valve implantation for patients with dysfunctional right ventricular outflow tracts (rvot).All data were retrospectively collected from a single center between january 1, 2010 and december 31, 2015.The study population included 246 patients who underwent pulmonary valve implantation (demographic data not provided), 106 of which were implanted with medtronic contegra bioprosthetic valved conduits, 29 with medtronic melody bioprosthetic valves, and 5 with medtronic hancock ii bioprosthetic valves.No serial numbers were provided.Among all patients, adverse events related to bioprosthetic valves or valved-conduits included: valve dislocations, insufficient reg urgitation, and surgical intervention.Based on the available information medtronic product may have been associated with these adverse events.No additional adverse patient effects or product performance issues were reported.
|